Zentalis Pharmaceuticals (ZNTL) Profit After Tax (2019 - 2026)

Zentalis Pharmaceuticals' Profit After Tax history runs 8 years deep, the most recent figure standing at -$35.4 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 26.78% year-over-year to -$35.4 million; the TTM figure through Mar 2026 stood at -$124.1 million (up 44.64% YoY), while the FY2025 annual figure was -$137.1 million, up 17.37% from the prior year.
• Profit After Tax for Q1 2026 stood at -$35.4 million, roughly flat from -$35.2 million in the prior quarter.
• The five-year high for Profit After Tax was $10.0 million in Q1 2024, with the low at -$112.6 million in Q2 2023.
• The 5-year median for Profit After Tax is -$54.4 million (2022), against an average of -$51.0 million.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax tumbled 1198.04% in 2022, then soared 115.88% in 2024.
• Zentalis Pharmaceuticals' Profit After Tax stood at -$55.0 million in 2022, then fell by 10.86% to -$60.9 million in 2023, then grew by 22.05% to -$47.5 million in 2024, then gained by 25.86% to -$35.2 million in 2025, then dropped by 0.39% to -$35.4 million in 2026.
• Business Quant data shows ZNTL's Profit After Tax at -$35.4 million in Q1 2026, -$35.2 million in Q4 2025, and -$26.7 million in Q3 2025.